Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum Antibiotics
Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum Antibiotics
批准号:
10326787
负责人:
Paul Hergenrother
金额:
$114.09万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-06 至 2024-01-31
关键词:
AcinetobacterAcuteAminesAnti-Bacterial AgentsAntibioticsAreaBacteriaBiological AssayCell membraneCellsChargeChemicalsClassificationCollectionComputational algorithmComputer ModelsCritical PathwaysDataDevelopmentDrug ScreeningDrug resistanceDrug usageEscherichia coliFailureFusidic AcidGram-Negative BacteriaGram-Negative Bacterial InfectionsGuidelinesIndividualInfectionLiteratureMembraneMethodsModelingMolecularMulti-Drug ResistanceMusMutateNational Institute of Allergy and Infectious DiseaseNaturePenetrancePharmaceutical PreparationsPropertyPseudomonas aeruginosaPublicationsResistanceScientistTrainingVDAC1 geneVariantWorld Health Organizationcarbapenem-resistant Enterobacteriaceaeefflux pumpexperimental studyflexibilityfunctional groupnovelnovel drug classoutcome predictionpathogenpathogenic bacteriapreventrandom forestscreeningsimulationtooltrait
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
The percent of Gram-negative bacterial infections that are resistant to common antibiotics has increased at an
alarming rate over the last decade, and there is now an acute need for the discovery of novel antibiotics effective
against multidrug-resistant Gram-negative pathogens. The standard method of antibacterial discovery – whole-
cell screening of compound collections – has met with repeated failure for Gram-negatives, and these failures
have been traced to the fact that very few compounds in standard collections can penetrate the Gram-negative
cell membranes and accumulate in these pathogens. Unfortunately, there has been scant information about the
types of compounds that are competent for accumulation in Gram-negatives. Excitingly, we recently assessed a
unique collection of >180 diverse compounds for their ability to accumulate in E. coli, trained a random forest
classification model to analyze the results, and from this data we identified physicochemical properties important
for accumulation and developed predictive guidelines for compound accumulation in E. coli. We then showed
the utility of these guidelines by converting a Gram-positive-only antibiotic into a broad-spectrum agent. We now
propose to develop tools that will allow us to fully define the physicochemical traits that enable compounds
accumulation in three of the most concerning Gram-negative bacteria, carbapenem-resistant
Enterobacteriaceae (CRE), drug-resistant Acinetobacter, and drug-resistant P. aeruginosa (to be referred to
collectively as EAP pathogens). Specifically, we seek to develop novel tools in the area of chemical probes
(compound collections), bacterial strains, and computational models. Using these tools in conjunction with our
well-validated compound accumulation assay, we intend to define the physicochemical traits needed for
compound accumulation in the EAP pathogens, including assessment of the influence of porins and efflux
pumps, and the relative contribution of the outer and inner-membranes to blocking compound penetrance. Our
predictive guidelines will be utilized to convert several high-value Gram-positive-only compounds into broad-
spectrum antibiotics.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1021/acsinfecdis.0c00715
发表时间:
2021-01-08
期刊:
ACS infectious diseases
影响因子:
5.3
作者:
[Perlmutter SJ, Geddes EJ, Drown BS, Motika SE, Lee MR, Hergenrother PJ]
通讯作者:
Hergenrother PJ
DOI:
10.1021/acsinfecdis.0c00869
发表时间:
2021-02-12
期刊:
ACS infectious diseases
影响因子:
5.3
作者:
[Garcia Chavez M, Garcia A, Lee HY, Lau GW, Parker EN, Komnick KE, Hergenrother PJ]
通讯作者:
Hergenrother PJ
DOI:
10.1021/acs.accounts.0c00895
发表时间:
2021-03-16
期刊:
Accounts of chemical research
影响因子:
18.3
作者:
[Muñoz KA, Hergenrother PJ]
通讯作者:
Hergenrother PJ
An LC-MS/MS assay and complementary web-based tool to quantify and predict compound accumulation in E. coli.
LC-MS/MS 测定和基于网络的补充工具,用于量化和预测大肠杆菌中的化合物积累。
DOI:
10.1038/s41596-021-00598-y
发表时间:
2021-10
期刊:
Nature protocols
影响因子:
14.8
作者:
[Geddes EJ, Li Z, Hergenrother PJ]
通讯作者:
Hergenrother PJ
DOI:
10.1126/science.abn8382
发表时间:
2022-04-15
期刊:
SCIENCE
影响因子:
56.9
作者:
[Ali, Siraj Z., Budaitis, Brenna G., Fontaine, Devon F. A., Pace, Andria L., Garwin, Jacob A., White, M. Christina]
通讯作者:
White, M. Christina
Developing a Suite of Targeted Anticancer Drugs
-
批准号:10734624
-
项目类别:
-
资助金额:$51.52万
-
财政年份:2023
-
负责人:Paul Hergenrother
-
依托单位:
FabI Inhibitors as Potent, Gut Microbiome-Sparing Antibiotics
-
批准号:10673319
-
项目类别:
-
资助金额:$97.78万
-
财政年份:2023
-
负责人:Paul Hergenrother
-
依托单位:
A Novel Therapeutic Strategy for Ovarian Cancer
-
批准号:10446419
-
项目类别:
-
资助金额:$59.78万
-
财政年份:2022
-
负责人:Paul Hergenrother
-
依托单位:
A Novel Therapeutic Strategy for Ovarian Cancer
-
批准号:10588222
-
项目类别:
-
资助金额:$58.72万
-
财政年份:2022
-
负责人:Paul Hergenrother
-
依托单位:
Training Program at the Chemistry Biology Interface
-
批准号:10202668
-
项目类别:
-
资助金额:$58.52万
-
财政年份:2020
-
负责人:Paul Hergenrother
-
依托单位:
Training Program at the Chemistry Biology Interface
-
批准号:10623229
-
项目类别:
-
资助金额:$63.66万
-
财政年份:2020
-
负责人:Paul Hergenrother
-
依托单位:
Training Program at the Chemistry Biology Interface
-
批准号:10441373
-
项目类别:
-
资助金额:$62.44万
-
财政年份:2020
-
负责人:Paul Hergenrother
-
依托单位:
Targeted Therapy for Head and Neck Cancer
-
批准号:10213008
-
项目类别:
-
资助金额:$36.74万
-
财政年份:2018
-
负责人:Paul Hergenrother
-
依托单位:
Targeted Therapy for Head and Neck Cancer
-
批准号:9764348
-
项目类别:
-
资助金额:$36.74万
-
财政年份:2018
-
负责人:Paul Hergenrother
-
依托单位:
Targeted Therapy for Head and Neck Cancer
-
批准号:10413177
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2018
-
负责人:Paul Hergenrother
-
依托单位:
Defining Parameters for Compound Accumulation in Gram-Negative Pathogens
-
批准号:9237555
-
项目类别:
-
资助金额:$32.95万
-
财政年份:2017
-
负责人:Paul Hergenrother
-
依托单位:
Design, Synthesis, and Evaluation of Lactate Dehydrogenase Inhibitors
-
批准号:8610324
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2012
-
负责人:Paul Hergenrother
-
依托单位:
Design, Synthesis, and Evaluation of Lactate Dehydrogenase Inhibitors
-
批准号:8296996
-
项目类别:
-
资助金额:$46.0万
-
财政年份:2012
-
负责人:Paul Hergenrother
-
依托单位:
Design, Synthesis, and Evaluation of Lactate Dehydrogenase Inhibitors
-
批准号:8464748
-
项目类别:
-
资助金额:$41.13万
-
财政年份:2012
-
负责人:Paul Hergenrother
-
依托单位:
Design synthesis and evaluation of lactate dehydrogenase inhibitors
-
批准号:8896143
-
项目类别:
-
资助金额:$7.32万
-
财政年份:2012
-
负责人:Paul Hergenrother
-
依托单位:
Design, Synthesis, and Evaluation of Lactate Dehydrogenase Inhibitors
-
批准号:8811978
-
项目类别:
-
资助金额:$42.15万
-
财政年份:2012
-
负责人:Paul Hergenrother
-
依托单位:
A Walk-UP LC-MS for the Rapid Analysis of Organic Compounds
-
批准号:7792972
-
项目类别:
-
资助金额:$29.93万
-
财政年份:2010
-
负责人:Paul Hergenrother
-
依托单位:
Small Molecule Activators of Procaspases as Anti-Cancer Agents
-
批准号:7910330
-
项目类别:
-
资助金额:$30.48万
-
财政年份:2009
-
负责人:Paul Hergenrother
-
依托单位:
Targeting CUG Expansions for the Treatment of Myotonic Dystrophy
-
批准号:8530952
-
项目类别:
-
资助金额:$28.98万
-
财政年份:2009
-
负责人:Paul Hergenrother
-
依托单位:
Small Molecule Activators of Procaspases as Anti-Cancer Agents
-
批准号:8081814
-
项目类别:
-
资助金额:$46.97万
-
财政年份:2007
-
负责人:Paul Hergenrother
-
依托单位:
海外基金